文献速递帕金森病与运动障碍

LRRK2突变携带者中较高尿酸水平与帕金森病抵抗相关

Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.
PubMed 文献 · Ann Neurol · 2019-03-03

本研究探讨尿酸是否调节LRRK2突变携带者的帕金森病风险。在三个独立队列中,未发病的LRRK2突变携带者尿酸水平显著高于发病者,荟萃分析显示调整后平均差异为0.62 mg/dL(p < 0.001),尿酸每增加2 mg/dL,患帕金森病的比值比约为0.48(p = 0.004)。结论认为尿酸是LRRK2突变携带者抵抗帕金森病的生物标志物。

要点

  • 未发病LRRK2突变携带者尿酸水平显著高于发病者。
  • 尿酸每升高2 mg/dL,帕金森病风险降低约50%。
  • 尿酸可能作为LRRK2突变携带者帕金森病抵抗的生物标志物。

核心结论

  • 尿酸是LRRK2突变携带者抵抗帕金森病的生物标志物。

研究设计与样本

  • 研究纳入LRRK2队列联盟的试点研究192例和验证研究380例,以及帕金森进展标志物计划的922例,按年龄和性别匹配。
  • 比较有和无帕金森病诊断的受试者尿酸水平,条件于LRRK2状态,控制年龄和性别。

主要发现

  • 在三个独立队列中,未发病的LRRK2突变携带者尿酸水平均显著高于发病者。
  • 荟萃分析显示调整后平均差异为0.62 mg/dL(p < 0.001),女性和男性分别评估结果相似(p < 0.02和p < 0.001)。
  • 尿酸浓度每增加2 mg/dL,患帕金森病的比值比约为0.48(p = 0.004)。

临床怎么用

  • 在LRRK2突变携带者中,可考虑监测尿酸水平以评估帕金森病风险。
  • 尿酸水平较高可能提示对帕金森病的抵抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: LRRK2 mutations, the most common genetic cause of Parkinson disease (PD), display incomplete penetrance, indicating the importance of other genetic and environmental influences on disease pathogenesis in LRRK2 mutation carriers. The present study investigates whether urate, an antioxidant, Nrf2 activator, and inverse risk factor for idiopathic PD, is one such candidate biomarker of PD risk modulation in pathogenic LRRK2 mutation carriers. METHODS: Banked plasma samples or urate levels were obtained for 3 cohorts of age- and sex-matched subjects with and without a known LRRK2 mutation in PD and unaffected controls to conduct a pilot study of 192 subjects from the LRRK2 Cohort Consortium (LCC) and 2 validation studies of 380 additional subjects from the LCC and 922 subjects from the Parkinson's Progression Markers Initiative. Urate levels were compared by multiple regression between subjects with and without a PD diagnosis conditional on LRRK2 status, controlling for age and sex. RESULTS: Nonmanifesting LRRK2 mutation carriers had significantly higher levels of urate than those who developed PD in each of the 3 independent cohorts. A meta-analysis demonstrated an adjusted mean difference of 0.62 mg/dL (p < 0.001), with similar results for separate assessments of women (p < 0.02) and men (p < 0.001). A 2 mg/dL increment in urate concentration decreased the odds of having PD by approximately 50% (odds ratio = 0.48, p = 0.004). INTERPRETATION: These findings identify and substantiate urate as a biomarker of resistance to PD among LRRK2 mutation carriers. Ann Neurol 2019;85:593-599.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Bakshi R, Macklin EA, Logan R, et al. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019. PMID: 30761591. doi:10.1002/ana.25436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。